Prospective Grant of an Exclusive Patent License: Use of A CD47 Phosphorodiamidate Morpholino Oligomer for the Treatment, Prevention, and Diagnosis Of Cancer

Riepilogo

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Morphiex Biotherapeutics ("Morphiex") located in Boston, MA.